Fig. 4.
Fig. 4. Pretreatment with KF41399 suppressed the decrease and accelerated the recovery of each lineage of MNC. / (A) Time course of the phenotype of MNC derived from ACNU-treated mice. Mice were administered 45 mg/kg ACNU IV for 2 consecutive days, on day 3 and day 4 (protocol I, Table 1). Control animals were administered distilled water (protocol A, Table 1). MNC was prepared on indicated days, and the phenotype of MNC was analyzed by FACScan as described in “Materials and methods.” (B) Time course of the phenotype of MNC derived from the KF41399 pretreated mice. Mice were treated with 25 mg/kg KF41399 orally twice daily for 10 days, from day 0 to day 9, followed by the IV administration of 45 mg/kg ACNU for 2 consecutive days, on day 3 and day 4 (protocol H, Table 1). Results are expressed as the mean ± SD. n = 5 in each group.

Pretreatment with KF41399 suppressed the decrease and accelerated the recovery of each lineage of MNC.

(A) Time course of the phenotype of MNC derived from ACNU-treated mice. Mice were administered 45 mg/kg ACNU IV for 2 consecutive days, on day 3 and day 4 (protocol I, Table 1). Control animals were administered distilled water (protocol A, Table 1). MNC was prepared on indicated days, and the phenotype of MNC was analyzed by FACScan as described in “Materials and methods.” (B) Time course of the phenotype of MNC derived from the KF41399 pretreated mice. Mice were treated with 25 mg/kg KF41399 orally twice daily for 10 days, from day 0 to day 9, followed by the IV administration of 45 mg/kg ACNU for 2 consecutive days, on day 3 and day 4 (protocol H, Table 1). Results are expressed as the mean ± SD. n = 5 in each group.

Close Modal

or Create an Account

Close Modal
Close Modal